Liver-Targeting of Interferon-Alpha with Tissue-Specific Domain Antibodies

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Coulstock, Edward ^a   Sosabowski, Jane ^b   Ovečka, Milan ^a   Prince, Rob ^a   Goodall, Laura ^a   Mudd, Clare ^a,c   Sepp, Armin ^a   Davies, Marie ^a   Foster, Julie ^b   Burnet, Jerome ^b   Dunlevy, Gráinne ^a   Walker, Adam ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Molecular Biotechnology Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON ASIALOGLYCOPROTEIN RECEPTOR DOMAIN ANTIBODY FUSION PROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE FUSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; MOUSE; NONHUMAN; PHAGE DISPLAY; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE CULTURE; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIBODIES; HUMANS; INTERFERON-ALPHA; LIVER; MICE; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84874381206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057263     Document Type: Article

References (34)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 347: 975-982.
2. Fried MW, Hadziyannis SJ, (2004) Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 24: 47-54.
3. Platanias LC, (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5: 375-386.
4. Dusheiko G, (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26: 112S-121S.
5. Iorio R, Pensati P, Botta S, Moschella S, Impagliazzo N, et al. (1997) Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 16: 984-990.
6. Dieperink E, Ho SB, Thuras P, Willenbring ML, (2003) A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44: 104-112.
7. Wu AM, Senter PD, (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23: 1137-1146.
8. Iyer U, Kadambi VJ, (2011) Antibody drug conjugates- Trojan horses in the war on cancer. J Pharmacol Toxicol Methods 64: 207-212.
9. Van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG, (2004) Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 64: 4357-4365.
10. Pardridge WM, (2010) Biopharmaceutical drug targeting to the brain. J Drug Targeting 18: 157-167.
11. Spiess M, Lodish HF, (1985) Sequence of a second human asialoglycoprotein receptor: conservation of two receptor genes during evolution. Proc Natl Acad Sci USA 82: 6465-6469.
12. Deal KA, Cristel ME, Welch MJ, (1998) Cellular distribution of 111In-LDTPA galactose BSA in normal and asialoglycoprotein receptor-deficient mouse liver. Nucl Med Biol 25: 379-385.
13. Saunier B, Triyatni M, Ulianich L, Maruvada P, Yen P, et al. (2003) Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol 77: 546-559.
14. Seow YY, Tan MG, Woo KT, (2002) Expression of a functional asialoglycoprotein receptor in human renal proximal tubular epithelial cells. Nephron 91: 431-438.
15. Pacifico F, Montuori N, Mellone S, Liguoro D, Ulianich L, et al. (2003) The RHL-1 subunit of the asialoglycoprotein receptor of thyroid cells: cellular localization and its role in thyroglobulin endocytosis. Mol Cell Endocrinol 208: 51-59.
16. Park JH, Cho EW, Shin SY, Lee YJ, Kim KL, (1998) Detection of the asialoglycoprotein receptor on cell lines of extrahepatic origin. Biochem Biophys Res Commun 244: 304-311.
17. Jeong YI, Seo SJ, Park IK, Lee HC, Kang IC, et al. (2005) Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm 296: 151-161.
18. Zhang XQ, Wang XL, Zhang PC, Liu ZL, Zhuo RX, et al. (2005) Galactosylated ternary DNA/polyphosphoramidate nanoparticles mediate high gene transfection efficiency in hepatocytes. J Controlled Release 102: 749-763.
19. Zhang Y, Qi XR, Gao Y, Wei L, Maitani Y, et al. (2007) Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J Controlled Release 117: 281-290.
20. Duncan R, Seymour LCW, Scarlett L, (1986) Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim Biophys Acta Gen Subj 880: 62-71.
21. Peng DJ, Sun J, Wang YZ, Tian J, Zhang YH, et al. (2007) Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor. Cancer Gene Ther 14: 66-73.
22. Eto T, Takahashi H, (1999) Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Nat Med 5: 577-581.
23. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G, (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341: 544-546.
24. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM, (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21: 484-490.
25. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, et al. (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 21: 283-288.
26. Loignon M, Perret S, Kelly J, Boulais D, Cass B, et al. (2008) Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnology 8: 65.
27. Trahtenherts A, Benhar I, (2009) An internalizing antibody specific for the human asialoglycoprotein receptor. Hybridoma 28: 225-233.
28. Walker A, Dunlevy G, Rycroft D, Topley P, Holt L, et al. (2010) Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel 23: 271-8.
29. Treichel U, Meyer zum Büschenfelde KH, Stockert R, Poralla T, Gerken G, (1994) The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol 75: 3021-3029.
30. Yang DY, Ouyang CH, Lu FG, Liu XW, Huang LQ, (2007) Targeting specificity and pharmacokinetics of asialoorosomucoid, a specific ligand for asialglycoprotein receptor on hepatocyte. J Dig Dis 8: 89-95.
31. Abe M, Lai J, Kortylewicz ZP, Nagata H, Fox IJ, et al. (2003) Radiolabeled constructs for evaluation of the asialoglycoprotein receptor status and hepatic functional reserves. Bioconjugate Chem 14: 997-1006.
32. Kallinteri P, Liao WY, Antimisiaris SG, Hwang KHJ, (2001) Characterization, stability and in-vivo distribution of asialofetuin glycopeptide incorporating DSPC/CHOL liposomes prepared by mild cholate incubation. J Drug Targeting 9: 155-168.
33. Gay R, Clarke A, Elgundi Z, Domagala T, Simpson R, et al. (2010) Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs 2: 625-638.
34. Kabat EA, Wu TT, Perry H, Gottesman K (1991) Sequences of Proteins of Immunological Interest, 5th edition. Bethesda, MD: United States Department of Health and Human Services.